CSIMarket
 


Kintara Therapeutics Inc   (KTRA)
Other Ticker:  
 

Cumulative Kintara Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

KTRA's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

KTRA Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
(Sep 30 2022)
I. Quarter
Y / Y Current Liabilities Growth -5.12 % -22.76 % -13.89 % -5.79 % 17.16 %
Y / Y Current Assets Growth -90.4 % -75.34 % -40.39 % -38.81 % -59.44 %
Working Capital Ratio for Trailing Twelve Months Period 1.55 2.11 2.7 2.91 3.28
Total Ranking # 2250 # 1813 # 1521 # 1635 # 1472
Seq. Current Liabilities Growth 8.24 % 10.47 % -13.86 % -7.88 % -11.88 %
Seq. Current Assets Growth -76.06 % -45.64 % -34.45 % 12.53 % -38.48 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite year on year decrease in Kintara Therapeutics Inc 's average Current Liabilities to $3 millions, Working Capital Ratio for Trailing Twelve Months Period to 1.55 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 477 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Kintara Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about KTRA
Working Capital Ratio KTRA in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 478
Sector # 991
S&P 500 # 3683


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
6.62 4.3 1.55
(Jun 30 2021)   (Sep 30 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Reviva Pharmaceuticals Holdings Inc   4.23 
Procyon Corporation  4.21 
Neubase Therapeutics inc   4.19 
Corvus Pharmaceuticals Inc   4.16 
Benitec Biopharma Inc   4.16 
Travere Therapeutics Inc   4.10 
Liminal Biosciences Inc   4.09 
Theriva Biologics inc   4.04 
Ocular Therapeutix Inc   4.04 
Horizon Therapeutics Public Limited Company  4.03 
Tg Therapeutics Inc   4.00 
Puretech Health Plc  3.99 
Arvinas Inc   3.98 
Casi Pharmaceuticals inc   3.97 
Pacira Biosciences inc   3.96 
Axsome Therapeutics Inc   3.96 
Biomarin Pharmaceutical Inc  3.95 
Hookipa Pharma inc   3.94 
Mustang Bio inc   3.90 
Genelux Corporation  3.89 
Alpine Immune Sciences Inc   3.88 
Acurx Pharmaceuticals inc   3.87 
Onconova Therapeutics inc   3.83 
Immunome Inc  3.79 
Elicio Therapeutics Inc   3.77 
Prophase Labs Inc   3.75 
Enveric Biosciences Inc   3.75 
Arcturus Therapeutics Holdings Inc   3.75 
Calithera Biosciences Inc   3.69 
Ani Pharmaceuticals Inc  3.67 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com